Karl G. Blume

Align Technology (United States) — United States

Medicine · Health Sciences

60h-index16.7kcitations227works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(117), Acute Myeloid Leukemia Research(35), Immune Cell Function and Interaction(30), T-cell and B-cell Immunology(27), Lymphoma Diagnosis and Treatment(27)

Publications227 total

A-381 Nanowire assisted fluorescence immunoassay (FLIA): Enabling low-cost, high-sensitivity biomarker assays for expanded clinical utility
Clinical Chemistry·2025Open Access
New Pre-Transplant Regimens
2020
A New High-Affinity Hemoglobin
2017
A History of Allogeneic and Autologous Hematopoietic Cell Transplantation
2015· 4 cited
One million haemopoietic stem-cell transplants: a retrospective observational study
The Lancet Haematology·2015· 426 cited
Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation
Journal of Clinical Oncology·2013· 210 citedOpen Access
E. Donnall Thomas (1920–2012)
Proceedings of the National Academy of Sciences·2012· 8 citedOpen Access
Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies
JAMA·2011· 316 citedOpen Access
Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells
Biology of Blood and Marrow Transplantation·2011· 48 citedOpen Access
Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors
Blood·2010
Patients Beware: Commercialized Stem Cell Treatments on the Web
Cell stem cell·2010· 52 citedOpen Access
Autologous hematopoietic cell transplantation for high-risk ALL
Bone Marrow Transplantation·2010· 10 cited
Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
Bone Marrow Transplantation·2010· 10 cited
Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
Biology of Blood and Marrow Transplantation·2010· 20 citedOpen Access
In the Right Place at the Right Time
The Hematologist·2010
First wave of the influenza A/H1N1v pandemic in Switzerland
Swiss Medical Weekly·2009· 8 citedOpen Access
Long-term outcomes of high-dose therapy using busulfan, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for patients with high-risk or advanced stages of myeloid malignancies
Journal of Clinical Oncology·2009
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Blood·2009· 164 citedOpen Access
Front Matter
2009
Index
2009Open Access
page 1 of 12Next →

Frequent Co-authors

Rainer Storb(18), Stephen J. Forman(15), Brenda M. Sandmaier(14), David G. Maloney(14), Barry E. Storer(14), Thomas R. Chauncey(13), Robert S. Negrin(12), Michael B. Maris(12), Peter A. McSweeney(10), Dietger Niederwieser(10), Judith A. Shizuru(9), Keith Stockerl‐Goldstein(9), Benedetto Bruno(9), Laura Johnston(8), Frederick R. Appelbaum(7), Michael A. Pulsipher(7), Wendy Hu(7), Ute Hegenbart(6), Mary E.D. Flowers(6), Monic J. Stuart(6)